Kala Pharmaceuticals Garners $68,000,000 Series C Funding Round

  • Feed Type
  • Date
    4/14/2016
  • Company Name
    Kala Pharmaceuticals
  • Mailing Address
    100 Beaver St. Waltham, MA 02453 USA
  • Company Description
    Kala Pharmaceuticals, Inc. is a biotechnology company founded upon a proprietary drug delivery technology. By utilizing this unique technology, Kala aims to address unmet therapeutic needs of various diseases and conditions in a fundamentally novel way.
  • Website
    http://www.kalarx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $68,000,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    The proceeds of the financing will be used to advance the confirmatory Phase 3 trial for KPI – 121 for the treatment of inflammation and pain following cataract surgery, two parallel P hase 3 studies for KPI – 121 in dry eye disease, and for general corporate purposes.
  • M&A Terms
  • Venture Investor
    Longitude Capital Management
  • Venture Investor
    OrbiMed
  • Venture Investor
    Vivo Capital
  • Venture Investor
    RA Capital
  • Venture Investor
    Polaris Partners
  • Venture Investor
    Lux Capital
  • Venture Investor
    CVF

Trending on Xconomy